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Background: Before establishing a prospective cohort, an initial pilot study is recommended. However, there are
no precise guidelines on this subject.
This paper reports the findings of a French regional pilot study carried out in three nephrology departments, before
realizing a major prospective Non Dialysis Chronic Renal Insufficiency study (ND-CRIS).
Methods: We carried out an internal pilot study. The objectives of this pilot study were to validate the feasibility
(regulatory approval, providing patients with information, availability of variables, refusal rate of eligible patients)
and quality criteria (missing data, rate of patients lost to follow-up, characteristics of the patients included
and non-included eligible patients, quality control of the data gathered) and estimate the human resources
necessary (number of clinical research associates required).
Results: The authorizations obtained (CCTIRS – CNIL) and the contracts signed with hospitals have fulfilled
the regulatory requirements. After validating the information on the study provided to patients, 1849 of them
were included in three centres (university hospital, intercommunal hospital, town hospital) between April 2012
and September 2015. The low refusal rate (51 patients) and the characteristics of non-included patients have
confirmed the benefit for patients of participating in the study and provide evidence of the feasibility and
representativeness of the population studied. The lack of missing data on the variables studied, the quality of the data
analyzed and the low number of patients lost to follow-up are evidence of the quality of the study. By taking into
account the time spent by CRAs to enter data and to travel, as well as the annual patient numbers in each hospital,
we estimate that five CRAs will be required in total.
Conclusion: With no specific guidelines on how to realize a pilot study before implementing a major prospective
cohort, we considered it pertinent to report our experience of P-ND-CRIS. This experience confirms that i) feasibility, ii)
quality of data and iii) evaluating the resources required must be validated before carrying out a large prospective
cohort study such as ND-CRIS.
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The importance of conducting epidemiological co-
horts in France has been highlighted on several occa-
sions [1]. Chronic kidney disease (CKD) places a
heavy burden on health services, and it is becoming
increasingly common [2]. End-stage renal disease
(ESRD) is only the tip of the CKD iceberg [3]. With
early diagnosis and treatment, it is possible to slow
the progression of kidney disease [3–5]. The preva-
lence in France of chronic renal insufficiency with
GFR < 60 ml/mn/1.73 m2 has been estimated at 8.2%
according to the Mona Lisa study in a French popula-
tion of patients aged between 35 and 75 [6] and 12%
in patients aged > 65 in the 3C Study [7].
There are few prospective cohort studies on CKD.
There is no long-running epidemiological study on pre-
dialysis CKD, and incident cohorts are also lacking in
France [8].
This is why we set up the Non-Dialysis Chronic
Renal Insufficiency Study (ND-CRIS), a prospective
cohort of patients managed in the nephrology units
of a French region (Bourgogne Franche-Comté).
The primary aim of the ND-CRIS cohort is to describe
the ND-CRIS population followed by nephrologists in
the Bourgogne-Franche-Comté region (eastern France).
It is intended to provide regular information on thera-
peutic care and on the biological tests prescribed by
physicians in the centres. The quality of the care pro-
vided is assessed using indicators based on those recom-
mended by ANAES and HAS.
The ND-CRIS cohort is also designed to describe
the outcomes of patients included until they require
replacement therapies (dialysis, transplant, etc.). It
also intends to describe outcomes in terms of the
characteristics of this population. It thus provides
information on epidemiological trends among patients
with CKD in the Bourgogne-Franche-Comté region.
This information will facilitate ad hoc studies
assessing the risk-benefit ratio of health products and
actions.
However, a cohort study, which requires considerable
resources, cannot always be implemented for feasibility
reasons, especially if it is undertaken in more than one
hospital with no temporal horizon.
Before launching a study on this scale, a pilot study
should be performed as recommended in the good
practice guidelines for epidemiology [9]. However, unlike
for clinical trials [10], there are no guidelines to our
knowledge on how to conduct pilot cohort studies.
Having carried out a pilot study in three of the nine
nephrology departments in Bourgogne Franche-Comté,
we believe our experience could assist other epidemi-
ology researchers, particularly in the field of chronic
diseases such as renal insufficiency.The aim of this pilot study was to validate feasibility
and the quality of the data, and estimate the resources
required to extend the cohort to six other hospitals in
the Bourgogne-Franche-Comté region.Methods
Population
The population consisted of adult patients (>18 years)
with chronic kidney disease (CKD) who had follow-up
appointments with nephrologists in the hospitals of
Mâcon, Belfort-Montbéliard and Besançon University
Hospital.
The eligible population consisted of patients
presenting with CKD with a GFR < 60 ml/min/
1.73 m2, calculated using the MDRD method (stages
3 to 5: CKD stage defined as an estimated GFR of
45–59 (stage 3a), 30–44 (stage 3b), 15–29 (stage 4)
and <15 (stage 5) ml/min/1.73 m2) and not receiving
dialysis [11].
The population included patients presenting CKD
with two measurements of GFR < 60 ml/min/1.73 m2
calculated with the MDRD method and not receiv-
ing dialysis.Methods
Aims
To validate feasibility, we intended to i: ensure that
all hospitals were fully committed to the study before
the pilot study was conducted in three hospitals (pre-
test), ii: obtain regulatory approval and authorization
at a national level (CCTIRS and CNIL) and at a re-
gional level (hospitals), iii: undertake the process of
providing patients with information (comprehension
test and information leaflet), iiii: ensure that the vari-
ables of interest were present and accessible in the
medical files.
To validate the quality of the data, we focused on i:
analyzing characteristics of the patients included and
non-included eligible patients and comparing these
two groups to ensure the population studied was rep-
resentative of this type of population, ii: measuring
missing data and the rate of patients lost to follow-
up, iii: checking the quality of data collected during
appointments, enabling us to verify the data gathered
by the CRAs.
The necessary resources (number of CRAs) were
estimated based on the average time required for a
CRA to enter patient data into the CRF, the time
required by CRAs to travel to the participating
hospitals, and the potential number of patients in
each nephrology unit in the Bourgogne-Franche-
Comté region.
Massol et al. BMC Nephrology  (2017) 18:46 Page 3 of 9Design
This was an internal pilot study on a prospective co-
hort with no predefined temporal horizon, i.e. the pa-
tients included and followed in the pilot study would
be included in the ND-CRIS cohort, and their follow-
up continued.
Duration
This pilot study was conducted between April 2012
and September 2015 in three of the nine hospitals in
the region. The duration of three years was chosen
because it was consistent with the frequency of
follow-up consultations for patients with non-dialysis
CKD (at least one consultation per year), as reported
by the investigators.
Pre-test
Before the cohort was established, a pre-test phase was
designed to ascertain the commitment of the manage-
ment and nephrology teams in each hospital. It was
done during face to face meetings in each centre of
nephrology. The main objective of these meetings was to
obtain insurance of their commitment. During these
meetings, comments and remarks have been integrated
into the protocol. No formal survey was necessary to
collect feedbacks.
Pilot phase
The pilot study consisted of the inclusion phase and
follow-up of patients. The CRAs were asked to search in
medical files for the main variables concerned (age, sex,
GFR, comorbidity – diabetes and hypertension and ex-
posure to medication) in both inclusion appointments
and follow-up consultations.
The present study was intended to refine the list of
variables and to finalize the initial protocol before sub-
mitting it for approval by the regulatory authorities
(CNIL and CCTIRS).
Meetings were held in each hospital to explain the
cohort project, and the different groups of patients were
evaluated during these meetings.
Inclusion/exclusion criteria
According to this protocol, which was accepted for
publication [12], patients were included if they presented
a GFR < 60 ml/min/1.73 m2, and if they did not refuse to
participate in the study as required by the French
legislation (see section “Ethics and Consent” of the
Declarations).
We excluded patients who had received transplants,
those who had undergone dialysis, those attending
occasional appointments in the participating hospitals
and patients who were unable to understand the infor-
mation leaflet.Definition of subjects lost to follow-up
The duration of the P-ND-CRIS cohort was adjusted ac-
cording to the estimated mean frequency of follow-up
consultations to obtain a group of patients included for
at least 18 months. This enabled us to assess the poten-
tial attrition rate.
Although the cohort involved all patients with a
GFR < 60 ml/mn/1.73 m2 managed in a nephrology
unit, nephrologists do not see patients with a GFR >
45 ml/mn systematically (this is the threshold beyond
which patients should be followed in nephrology
departments according to the HAS [13]).
The majority of patients whose GFR was between
45 and 60 ml/mn/1.73 m2 are managed by general
practitioners. These patients cannot therefore be con-
sidered as lost to follow up if they have not been
seen for 18 months. We therefore defined patients
lost to follow up as patients whose GFR was < 45 ml/
mn/1.73 m2 and had not been seen for at least
18 months.Data collection and data management
After obtaining access to medical files (in paper or
electronic form) from the hospital management team,
the Department of Medical information (DIM) and
the physician in charge of the department, three
CRAs identified eligible patients. The physicians then
explained the study to eligible patients and reported
to the CRAs to inform them of any refusals to take
part. Information on patient refusals was noted on
the consultation report or in the patient’s electronic
data file. Data were gathered by the CRAs in the
participating hospitals from medical files, using an
electronic case-report form (CRF). The data were
collected when the patient was included and at each
follow-up consultation (or hospitalization). The data
from each hospital were then transferred every three
months to the data manager and stored in an SAS
database.Coordination and compliance with good epidemiological
practice
The study as a whole was managed by a coordinat-
ing project leader, a steering committee and a
manager.
The collection, processing and storing of data
were performed in compliance with deontological
ethics and good epidemiological practice recommen-
dations (ADELF, ADEREST, AEEMA, EPITER)
[French 2007 version 9] and with the ISPE Guide-
lines for good pharmacoepidemiological practice
(GPP) [14].
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Age / gender/ area of residence / socio-professional status X
Date of consultation X x X
Creatininaemia X x X
Diagnosis of kidney disease X
Risk factors, complications and hospitalizations x X
Clinical examination: weight, height, blood pressure x X
Biological tests: proteinuria, microalbuminuria, calcaemia,
phosphoremia, haemoglobin, 25 OHD3, PTH, ferritin, iron,
saturation, CRF
x x
Examinations/imaging with injection of contrast substances x
Pharmacological treatment x x
Date and type of information on dialysis, date and method of
dialysis, date of fistula placement
x
Date and type of information on transplants. Date of transplant x
Death and cause x
Other reasons for removal from cohort (specify) xQuality control
At the end of the pilot phase, a quality assessment was
conducted in the three hospitals in order to determine
discrepancies between the variables listed in the CRFs
and those obtained from the medical files. Discrepancies
were classified as minor or major, according to criteria
defined by the steering committee.
Minor discrepancies were defined as having no impact
on patient characteristics (e.g. level of renal function
deterioration, identification of comorbidities or adminis-
tration of relevant medication). These minor discrepan-
cies sometimes involved collecting more recent
measurements from a medical file, an error in noting the
result of a titration schedule with no consequences for
the patient’s profile, the omission of a minor medication
excluded from the list of indicators defining the protocol
objectives, or failure to complete a variable in the CRF
when that variable was not related to the main cohort
objectives.
Major discrepancies were defined as having an impact
on the main patient characteristics. These include a
follow-up consultation omitted from the CRF, or a
comorbidity not noted in the CRF (failure to collect data
in a follow-up consultation; non-identification of cardiac
failure as a relevant comorbidity, non-identification of
ACE Inhibitor as a relevant treatment in the table of
treatments).
Statistical analyses
The patients included were described for all three hospi-
tals and for each hospital individually. The quantitativevariables were described using whole numbers, the number
of elements of data entered, means and standard deviation,
and extreme (min/max) values. The statistical tests were
two-tailed and the statistical significance threshold was set
at 5%. The statistical analyses were performed on SAS® soft-
ware, version 9.4, SAS Institute, NC, Cary, USA.Results
To validate the feasibility of the study, we sought the
agreement of the participating hospitals.
In addition to the three centres involved in the pilot
study, six other regional hospitals agreed to participate.
The cohort was thus extended to the whole region.
We tested the process of providing patients with infor-
mation. The patient leaflet was written according to
CCTIRS recommendations [15].
To test this process, we gave the leaflet to ten patients
and evaluated their understanding of it. This test helped
us to improve and validate the contents and the format
of the information leaflet.
We obtained approval from the regulatory authorities:
at a national level, the protocol was successively
approved by the CCTIRS and by the CNIL and at re-
gional level, agreements were signed with each of the
hospital management teams.
The availability and accessibility of the relevant vari-
ables in the medical files were reviewed.
The variables to be collected, which were initially
decided by the steering committee, were in the patient
files both during the inclusion period and during the
follow-up consultations. At the end of the pilot phase,
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mittee, and included in the CRF.
To validate the quality of the data obtained, the char-
acteristics of patients included and non-included eligible
patients were collected. These data were presented in
Tables 1 and 2.
Table 1 presents the characteristics of patients at the
time of inclusion.
Table 2 presents a comparison of the characteristics of
patients included and non-included eligible patients.
Because this was an observational study which aimed to
describe patient management, non-collected data were
not considered to be missing data. However, the data
deemed essential by the steering committee and which
could have been defined as missing data were always
accessible during the pilot study, except for the age of one
patient and diastolic blood pressure for one patient. These
data were as follows: for inclusion (age, sex, GFR, comor-
bidities, exposure to medication) and during follow-up
(GFR, death, transplant, start of dialysis treatment, expos-
ure to medication and onset of comorbidity).
The data on patients lost to follow-up are presented
in Table 3.
Of the 1371 patients included before March 31st 2014
with GFR < 45 ml/min/1.73 m2 and not seen at an ap-
pointment for at least 18 months, four patients were po-
tentially lost to follow-up, i.e. 0.3%.Table 1 Characteristics of patients at inclusion (in all 3 hospitals and
Total 3 hospitals
Number of patients 1849
Sex ratio M:F 1.46
Mean age in years 71.6
SD +/− 12.9
[min – max] [19 – 99]
Mean GFR (in ml/min/1.73 m2) 34.0
SD +/− 12.5
[min – max] [5 – 59.9]
GFR (in ml/min/1.73 m2)
< 15 133 - 7.2%
[15 – 30] 572 - 30.9%
[30 – 45] 730 - 39.5%
[45 – 60] 414 - 22.4%
Mean proteinuria (in g/24 h.) 1.0
SD +/− 2.1
[min – max] [0 – 26]
Diabetes 736 - 39.8%
Type I 40 - 2.2%
Type II 696 - 37.6%
Hypertension 1634 - 88.4%Of 1849 patients, 541 with a GFR < 60 ml/min/1.73 m2
had not been seen for an appointment for at least
12 months on 30 September 2014. These patients had
either not yet attended an appointment, were possibly
lost to follow up, or had been referred to their general
practitioner. This figure falls to 8 for patients with a
GFR < 45 ml/min/1.73 m2 not attending an appointment
for at least 12 months.
The results of the quality control are presented in Table 4.
The human resources required (number of CRAs) for
data gathering in hospitals were calculated based on the
pilot phase, taking into account differences in data entry
time according to the availability of patient files in the
hospitals, and the time required to ascertain the vital
status of patients, and based on the possibility of extend-
ing the study to other hospitals.
Table 5 presents the human resources required (CRAs)
and the estimated annual number of patients treated for
renal insufficiency in each hospital.
The exposure of patients at the time of inclusion to medi-
cation listed in the ANAES indicators [16] is presented in
Table 6 (raw data are available in the Additional file 1).
Discussion
The P-ND CRIS pilot study has enabled us to start the
ND-CRIS study. We believe the experience gained dur-





+/− 13.4 +/−12.2 +/−12.9
[19 – 99] [25 – 96] [20–98]
34.0 34.4 33.8
+/− 12.9 +/−12.4 +/−12.3
[5.6 – 59.9] [6.6 – 59.5] [5 – 58.8]
45 - 7.5% 31 – 6.5% 57 – 7.4%
193 - 32.2% 146 – 36.7% 233 -30.1%
220 - 36.7% 186 -39.1% 324 – 41.9%
141 - 23.5% 113 -23.7% 160 – 20.7%
1.1 1.1 1.0
+/− 2.3 +/− 1.8 +/− 1.9
[0 – 26] [0 – 13] [0 – 20.8]
220 - 36.8% 178 – 37.4% 338 – 43.7%
25 - 4.2% 6 – 1.3% 9 - 1.2%
195 - 32.6% 172 – 36.1% 329 - 42.5%
493 - 82.3% 451 – 94.7% 690 - 89.1%








Sex (n - %) (K) p = 0.53
Male 1097 – 59.3% 28 – 54.9%
Female 752 – 40.7% 23 – 45.1%
Mean age in years 71.6 70.2 (S) p = 0.47
SD +/− 12.9 +/− 14.1
[min – max] [19 – 99] [21 – 99]
Mean GFR (in ml/
min/1.73 m2)
34.0 36.1 (S) p = 0.29
SD +/− 12.5 +/− 13.0
[min – max] [5 – 59.9] [14.3 – 59.1]
GFR (in ml/
min/1.73 m2)
(F) p = 0.75
< 15 133 - 7.2% 2 - 3.9%
[15 – 30] 572 - 30.9% 16 - 31.4%
[30 – 45] 730 - 39.5% 19 - 37.3%
[45 – 60] 414 - 22.4% 14 - 27.5%
Diabetes 736 - 39.8% 18 - 35.3% (K) p = 0.52
Hypertension 1634 - 88.4% 40 - 78.4% (K) p = 0.03
Table 4 Quality control






Besançon 297 3.70% (11) 0.34% (1)
Mâcon 562 2.31% (13) 0.36% (2)
Belfort-
Montbéliard
444 3.15% (14) 0.45% (2)
Total 3 hospitals 1303 2.92% (38) 0.38% (5)
Check of quality of data gathered by CRAs at follow-up visits
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spective cohorts in the field of chronic diseases such as
CKD.
The feasibility, quality of data gathered and the evalu-
ation of the resources required were taken into account
in the design of the P-ND-CRIS pilot study.
As part of the feasibility assessment and before the
pilot study was launched, a pre-test phase was realized
to assess the willingness of nephrology departments
across Bourgogne-Franche-Comté to participate in theTable 3 Outcome of patients included and lost to follow-up
Outcome of 1849 patients included No. of patients
During follow-up 1686
. Including those not seen for at least
18 months with GFR > 45
302
Left study 159
. Including those who died 76
. Including those undergoing dialysis 68
. Including those receiving transplants 6
. Including those who changed hospitals 7
. Including those excluded for not meeting
inclusion criteria
2
Possible lost to follow-up of a population of
1371 patients with GFR < 45 included prior
to 31 March 2014 and not seen again for at
least 18 months
4study. In agreement with the nephrologists, this phase
confirmed the need for CRAs to collect the data with se-
cure access to electronic data. The involvement of the
nephrologists was also considered necessary, particularly
to validate the information collected by the CRAs. With-
out this initial review of the situation, the pilot phase
would not have been possible.
As far as the regulatory applications and the patient
information leaflet were concerned, the requirements
vary in different countries. In France, approval is re-
quired from the CCTIRS to establish an observational
cohort. The CCTIRS validates the patient information
and acts as an ethics committee. Approval is also re-
quired from the CNIL, which ensures that the data col-
lected remain anonymous.
The quality of the data collected is essential for any
epidemiological study, because unreliable data cannot be
compensated for in the statistical analysis. Data gather-
ing cannot be enforced in an observational study. How-
ever, a cohort must contain variables and relevant
outcomes if it is to be exploitable and informative.
In our experience, the pilot phase must allow sufficient
time to evaluate the availability of data to be collected at
inclusion and during follow-up. In order to have suffi-
cient inclusion and follow-up data, the P-ND-CRIS study
was conducted over a three year period. During thisTable 5 Human resources required (CRA) and annual number

















Total hospitals 10.5 5950
Table 6 Patient exposure to the medication listed in ANAES
indicators
Exposure of the 1849 patients Number of patients/%
At least one ACE inhibitor 578/31.3%
At least one ARA II 570/30.8%
At least one ACE inhibitor or one ARA II 998/54.0%
At least one ACE inhibitor and one ARA II 75/4.1%
Metformine 115/6.2%
At least one NSAID 65/3.5%
Aminoglycoside 0/0%
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accessibility of the relevant variables in the medical files,
both during the inclusion period and for the follow-up
consultations.
The early data in the pilot phase highlighted the need
to add some essential variables (HbA1c levels, albumi-
naemia, urinary urea, and urinary sodium) to be col-
lected prospectively during the extension phase. The
absence of data on vaccination status, in particular for
influenza and hepatitis B, led us to encourage practi-
tioners to include this information in their files, in
particular from CKD stage 3b. This enabled us to design
and improve the CRF.
One of the aims of the ND-CRIS cohort was to
carry out pharmacoepidemiological studies. It was
therefore necessary that information on all medication
prescribed to patients was collected, not simply those
mentioned by the national recommendations [16]. Ac-
cess to health insurance databases would be required
to obtain this information. However, given the care
taken by nephrologists regarding medication in renal
insufficiency patients, we know that the information
gathered in our pilot study is adequate. A request for
“matching” between the ND-CRIS database and the
health insurance databases will nonetheless be made
to the relevant authorities.
The data concerning exposure to different medication
were efficiently collected during the pilot study, and it
showed that the P-ND-CRIS population was not
prescribed nephrotoxic medication (aminoglycosides,
metformin and NSAIDS in particular) as outlined in the
ANAES guidelines [16]. However, the proportion of
patients exposed to an ACE inhibitor or an ARA2 drug
was 54%, which seems rather low given the number of
subjects with hypertension (88.4%). This could be
because this particular exposure was measured at inclu-
sion, and not after follow-up started in the nephrology
department. Finally, given the number of patients with
hypertension <130/80 Hg (22.9%, results not shown) it is
clear that great improvements can be made to achieve
renal protection in line with the recommendations.The quality assessment is an important element for
epidemiological research because insufficiently reliable
data can be detrimental to the analyses and affect
conclusions in unpredictable ways.
The quality assessment conducted in the three hospitals
on 1303 variables showed low rates of discrepancies
between data in the CRFs and data in the medical files.
The pilot study should guarantee the representative-
ness of the target population. To do this, baseline
characteristics of the non-included eligible population
must be compared with those of patients included.
The descriptive data presented here do not provide
evidence of any differences between eligible patients
who were included and those who were not.
The P-ND-CRIS population, which was consistent
across the three hospitals in the pilot study, is probably
representative of the population of CKD patients
followed up in the nephrology departments of the
Bourgogne-Franche-Comté region, and probably in
France as a whole. This national representativeness can
be checked once we have the results of the national
French cohort, CKD-Rein, which represents the whole
country [17].
In a major longitudinal cohort, it seems that limiting the
number of patients lost to follow-up is even more import-
ant than the rate of missing data in order to judge the
quality of the data. If data gathering cannot be enforced in
an observational study, we cannot consider all the
non-entered variables to be missing data. However, it is
essential that no data are missing with regards to the rele-
vant outcomes, which is the case in our pilot study.
As far as the patients lost to follow-up are concerned,
we should first define them. In a heterogeneous popula-
tion of patients followed by a nephrologist with GFR
<60 ml/min/1.73 m2, only patients who should have
attended further appointments with the nephrologist can
be considered as lost to follow-up. In France, general
practitioners are encouraged to identify and follow
patients with a GFR <60 ml/mn/1.73 m2. However,
according to the recommendations, GPs only refer
patients to nephrologists systematically in the event of
GFR below 45 ml/min/1.73 m2 [13] or if there are spe-
cific problems. Thus, since our population only concerns
patients followed by nephrologists, the ND-CRIS cohort
cannot claim to represent patients at stage 3a. In
addition, since only some of these patients are followed
in nephrology departments, with consultations some-
times 18 months apart, they were not included in our
definition of patients lost to follow-up. In our study, the
rate of patients lost to follow-up (0.3%) was well below
the threshold used as one of the quality criteria for CKD
cohorts [18].
Strategies designed to reduce the numbers lost to
follow-up should be assessed and implemented. Such
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Information should be gathered to characterize subjects
lost to follow-up such as vital status, or by referring to
birth and death registries.
Another important point for establishing a cohort
effectively is to plan the resources required, particularly
the CRAs. The main elements taken into account to esti-
mate resources were the annual number of patients per
hospital, the average time required to collect data per
patient at inclusion and in follow-up appointments and
the costs incurred for CRAs to travel to hospitals. We
calculate that 10.5 CRA days are required per week to man-
age the ND-CRIS cohort in the 9 hospitals in the region.
Conclusion
Without specific guidelines on conducting a pilot study
before establishing a major prospective study, we believe
our experience will prove useful for other researchers.
The P-ND-CRIS internal pilot study has demonstrated
the feasibility of the ND-CRIS cohort. It has enabled us
to plan and implement the ND-CRIS cohort, which
should contribute to the epidemiological study of kidney
disease in France, such as the REIN registry [21] and the
CKD-Rein cohort [17]. An internal pilot study enables
us to establish a cohort with a large number of patients
and well-organized follow-up from the start.
The strengths of the P-ND CRIS study were the large
sample of patients and the quality and accessibility of
data, with very few patients lost to follow-up. We expect
to recruit more than 5000 patients, which will, to our
knowledge, make the ND-CRIS cohort one of the largest
open prospective cohorts on pre-end stage CKD.
Additional file
Additional file 1: Description of data: Inclusion worksheet: patients’
characteristics at inclusion. (XLSX 1568 kb)
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